Darwin Increases Stake in Genmab A/S

COPENHAGEN, Denmark; October 2, 2026, Genmab A/S, an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines, announced that Darwin Global Management Limited, an investment firm, has increased its stake in the company. According to a statement, as of September 28, 2026, Darwin, through shares and American Depositary Receipts (ADRs) held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in the company.

Genmab, established in 1999, is headquartered in Copenhagen, Denmark, with a presence across North America, Europe, and Asia Pacific. The company is known for its innovative antibody-based therapeutic formats, including bispecific antibodies, antibody, drug conjugates (ADCs), immune-modulating antibodies, and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, with the goal of delivering transformative medicines to patients.

This development marks a significant shift in Genmab’s shareholder landscape, with Darwin’s increased stake potentially influencing the company’s strategic direction and future decisions. The company’s expansive portfolio of innovative antibody medicines and its commitment to advancing late-stage clinical pipelines underscore its ongoing dedication to improving patient outcomes.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. Company Announcement no. 39 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment

This announcement is part of a broader landscape of corporate news, highlighting the dynamic nature of the biotechnology sector and the evolving shareholder dynamics within companies like Genmab. The increase in Darwin’s stake could have implications for Genmab’s governance and operational strategies, potentially leading to changes in management, product development, and market positioning.

The company’s statement emphasizes the importance of maintaining transparency and adhering to regulatory requirements, as highlighted by the reference to the Danish Capital Markets Act. This development is significant for investors, stakeholders, and the broader biotechnology community, as it signals a shift in the company’s ownership structure and could influence future investment and strategic decisions.